share_log

Mineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month Low on Analyst Downgrade

Mineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month Low on Analyst Downgrade

由于分析师降级,Mineralys Therapeutics(纳斯达克股票代码:MLYS)创下12个月新低
Defense World ·  2023/03/18 13:30

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) reached a new 52-week low on Friday after Credit Suisse Group lowered their price target on the stock from $40.00 to $38.00. Credit Suisse Group currently has an outperform rating on the stock. Mineralys Therapeutics traded as low as $15.04 and last traded at $15.20, with a volume of 25683 shares traded. The stock had previously closed at $15.38.

Mineralys Therapeutics, Inc.(纳斯达克股票代码:MLYS — 获取评级)周五创下52周新低,此前瑞士信贷集团将该股的目标股价从40.00美元下调至38.00美元。瑞士信贷集团目前对该股的评级为跑赢大盘。Mineralys Therapeutics的交易价格低至15.04美元,最后一次交易价格为15.20美元,交易量为25683股。该股此前收于15.38美元。

Several other research firms also recently weighed in on MLYS. Guggenheim began coverage on Mineralys Therapeutics in a research report on Tuesday, March 7th. They set a "buy" rating and a $32.00 target price on the stock. Wells Fargo & Company initiated coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "overweight" rating and a $27.00 price objective on the stock. Evercore ISI assumed coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "outperform" rating on the stock. Stifel Nicolaus began coverage on Mineralys Therapeutics in a research note on Tuesday, March 7th. They issued a "buy" rating and a $45.00 target price for the company. Finally, Bank of America began coverage on Mineralys Therapeutics in a research note on Tuesday, March 7th. They set a "buy" rating and a $39.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $36.20.

其他几家研究公司最近也对MLYS进行了权衡。古根海姆在3月7日星期二的一份研究报告中开始报道Mineralys Therapeutics。他们为该股设定了 “买入” 评级和32.00美元的目标价格。富国银行在3月7日星期二的一份报告中开始报道Mineralys Therapeutics。他们对该股发布了 “增持” 评级和27.00美元的目标价格。Evercore ISI在3月7日星期二的一份报告中假设对Mineralys Therapeutics进行了报道。他们对该股发布了 “跑赢大盘” 评级。Stifel Nicolaus在3月7日星期二的一份研究报告中开始报道Mineralys Therapeutics。他们为该公司发布了 “买入” 评级和45.00美元的目标价格。最后,美国银行在3月7日星期二的一份研究报告中开始报道Mineralys Therapeutics。他们为公司设定了 “买入” 评级和39.00美元的价格目标。六位研究分析师对该股进行了买入评级,根据Marketbeat.com的数据,该股的共识评级为 “买入”,平均目标价为36.20美元。

Get
获取
Mineralys Therapeutics
Mineralys Therape
alerts:
警报:

Insider Buying and Selling at Mineralys Therapeutics

Mineralys Therapeutics 的内幕买入和

In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the stock in a transaction dated Tuesday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at $29,875,664. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the stock in a transaction dated Tuesday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at $29,875,664. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Scott Levy bought 6,250 shares of the firm's stock in a transaction that occurred on Tuesday, February 14th. The stock was bought at an average price of $16.00 per share, for a total transaction of $100,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 350,811 shares in the company, valued at $5,612,976. The disclosure for this purchase can be found here. Insiders have acquired 1,568,750 shares of company stock valued at $25,100,000 in the last quarter.

在其他新闻方面,董事Ra Capital Management, L.P. 在2月14日星期二的一笔交易中购买了该股的125万股。这些股票的平均成本为每股16.00美元,总交易额为20,000,000.00美元。交易完成后,该董事现在拥有该公司的1,867,229股股份,价值29,875,664美元。该交易是在向美国证券交易委员会提交的文件中披露的,该文件可在 美国证券交易委员会网站。在其他新闻方面,董事Ra Capital Management, L.P. 在2月14日星期二的一笔交易中购买了该股的125万股。这些股票的平均成本为每股16.00美元,总交易额为20,000,000.00美元。交易完成后,该董事现在拥有该公司的1,867,229股股份,价值29,875,664美元。该交易是在向美国证券交易委员会提交的文件中披露的,该文件可在 美国证券交易委员会网站。此外,首席财务官亚当·斯科特·利维在2月14日星期二进行的一笔交易中购买了该公司6,250股股票。该股以每股16.00美元的平均价格被买入,总交易额为100,000.00美元。收购完成后,首席财务官现在直接拥有该公司的350,811股股份,价值5,612,976美元。可以找到此次收购的披露信息 这里。内部人士在上个季度收购了价值25,100,000美元的1,568,750股公司股票。

Mineralys Therapeutics Stock Performance

矿业疗法股票表现

About Mineralys Therapeutics

关于 Mineralys Therapeu

(Get Rating)

(获取评分)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.

Mineralys Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发针对醛固酮异常升高引起的疾病的药物。Mineralys Therapeutics Inc 总部位于宾夕法尼亚州拉德诺。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Mineralys Therapeutics (MLYS)
  • This Small Tech With Big Growth Prospects Is Nearing A Buy Point
  • Don't Chase FedEx Higher, Wait For The Pullback
  • 3 Stocks For A Defensive Tech Portfolio
  • Milk the Dividends on These 3 Cash Cows
  • Europe Raises Interest Rates, Should the Fed Follow?
  • 免费获取 StockNews.com 关于 Mineralys Therapeutics(MLYS)的研究报告
  • 这家具有巨大增长前景的小型科技公司已接近买入点
  • 不要追高联邦快递,等着回调
  • 防御性科技投资组合的3只股票
  • 在这 3 头摇钱树身上挤出股息
  • 欧洲提高利率,美联储应该效仿吗?

Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Mineralys Therapeutics 的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Mineralys Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发